GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+30.14%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$415M
AUM Growth
+$415M
(+7%)
Cap. Flow
-$23.9M
Cap. Flow
% of AUM
-5.75%
Top 10 Holdings %
Top 10 Hldgs %
57.35%
Holding
49
New
15
Increased
7
Reduced
16
Closed
8
Top Buys
| 1 |
Heron Therapeutics
HRTX
|
$23.5M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$20.9M |
| 3 |
Pliant Therapeutics
PLRX
|
$14.3M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$10.5M |
| 5 |
BridgeBio Pharma
BBIO
|
$10.4M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$24M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$18.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
$14.5M |
| 4 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$12.1M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
$11.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$2.98B
| $30.7M | 7.39% | 850,000 -254,334 | -23% | -$9.18M |
|
2
Jazz Pharmaceuticals
JAZZ
$7.75B
| $28.7M | 6.9% | 215,000 +25,000 | +13% | +$3.33M |
|
|
PNT
3
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $27.5M | 6.63% | 3,560,984 +1,140,483 | +47% | +$8.82M |
|
|
ALPN
4
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $24.8M | 5.98% | 3,448,521 +2,909,702 | +540% | +$20.9M |
|
5
Travere Therapeutics
TVTX
$1.56B
| $23.8M | 5.73% | 966,108 -5,125 | -0.5% | -$126K |
|
|
6
Heron Therapeutics
HRTX
$207M
| $23.5M | 5.65% | +5,645,161 | New | +$23.5M |
|
7
KalVista Pharmaceuticals
KALV
$678M
| $22.5M | 5.42% | 1,551,719 +21,719 | +1% | +$315K |
|
|
8
Pliant Therapeutics
PLRX
$101M
| $21.8M | 5.24% | 1,041,737 +684,474 | +192% | +$14.3M |
|
9
Relmada Therapeutics
RLMD
$37.2M
| $18.9M | 4.55% | 510,000 -190,000 | -27% | -$7.03M |
|
10
Aclaris Therapeutics
ACRS
$209M
| $16M | 3.86% | 1,019,282 -63,718 | -6% | -$1M |
|
11
Vaxcyte
PCVX
$4B
| $14.4M | 3.47% | 600,000 -385,153 | -39% | -$9.24M |
|
12
Galapagos
GLPG
$2.07B
| $13.1M | 3.15% | 306,411 -53,589 | -15% | -$2.28M |
|
13
Acumen Pharmaceuticals
ABOS
$82.4M
| $12M | 2.9% | 1,200,000 -315,000 | -21% | -$3.16M |
|
14
Alkermes
ALKS
$4.78B
| $11.3M | 2.73% | 507,500 +145,864 | +40% | +$3.26M |
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $10.5M | 2.52% | +76,500 | New | +$10.5M |
|
|
16
BridgeBio Pharma
BBIO
$9.89B
| $10.4M | 2.51% | +1,050,000 | New | +$10.4M |
|
|
CINC
17
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $9.89M | 2.38% | 301,324 -367,876 | -55% | -$12.1M |
|
18
Ventyx Biosciences
VTYX
$171M
| $9.43M | 2.27% | 269,967 -119,256 | -31% | -$4.16M |
|
|
TCDA
19
DELISTED
Tricida, Inc. Common Stock
TCDA
| $9.12M | 2.2% | 870,000 -294,763 | -25% | -$3.09M |
|
20
RAPT Therapeutics
RAPT
$188M
| $7.58M | 1.82% | +315,000 | New | +$7.58M |
|
21
UroGen Pharma
URGN
$900M
| $7.27M | 1.75% | 873,424 | – | – |
|
22
Replimune Group
REPL
$422M
| $6.74M | 1.62% | +390,000 | New | +$6.74M |
|
23
Madrigal Pharmaceuticals
MDGL
$9.76B
| $6.21M | 1.49% | +95,500 | New | +$6.21M |
|
24
Milestone Pharmaceuticals
MIST
$156M
| $6.2M | 1.49% | +674,656 | New | +$6.2M |
|
25
89bio
ETNB
$1.34B
| $5.53M | 1.33% | 955,000 -445,000 | -32% | -$2.58M |
|